Worldwide Clinical Trials appoints Evelyn Graham

To lead sales, marketing and business development for late-stage business

Worldwide Clinical Trials, a US-based global contract research organisation, has appointed Evelyn Graham as executive vice president, Global Business Development.

With more than 20 years of drug development experience, Graham will lead sales, marketing and business development strategies for the late stage business.

Graham was formerly chief executive of TorreyPines Therapeutics and led the company’s merger with Raptor Pharmaceuticals in September 2009.

You may also like

Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Manufacturing

Isopod Rapid Cleanrooms – the elite modular systems saving your host building from unwanted modifications

Suffolk-based cleanroom construction specialists the Guardtech Group have the perfect modular solution for clients who need to keep their host rooms intact
Manufacturing

Hongene Biotech to manufacture Hangzhou Biotech's siRNA-based dyslipidaemia therapy

The CDMO will manufacture raw materials for the clinical development of DNV001, a novel therapy for the treatment of dyslipidaemia
Subscribe now